Market Overview

Flu Activity Continues to Rise, Related Prescriptions Up 12% from Last Week; Watch CVS, Walgreen

Share:
Related CVS
JP Morgan Downgrades Omnicare Following CVS Deal
Oppenheimer's 10 'Best Of The Best' Technical Buy Ideas
CVS Health's Q2 Earnings, Sales Growth Seen Slowing (Investor's Business Daily)
Related WAG
CVS Photo Site Reportedly Hacked: Everything You Need To Know
IPO Outlook: API-Focused Software Tech Company Apigee Is A Silent Growth Story

Lazard Capital Market's Tom Galluci issued an update on flu activity Monday morning following a note from December 17th which suggested CVS (NYSE: CVS) and Walgreen (NYSE: WAG) could benefit from increased cases of the virus.

The analyst said flu activity was up 12 percent from last week and up a very concerning 94 percent from the same week last year. Prescriptions for cold, cough and/or flu drugs has surged 61 percent from December 2011.

Galluci believes this increase in activity is likely to have a greater effect on hospital volume metrics rather than earnings as a lower-margin business.

Lazard maintains a Buy rating on CVS and a Neutral rating on Walgreen shares.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onOutperform
Jun 2015Cowen & CompanyMaintainsOutperform
Jun 2015MacquarieInitiates Coverage onOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (CVS + RAD)

Get Benzinga's Newsletters